Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625758 | 1.00 | REN (0.43) | RENCTSKCTSSCTSLCTSB | |
| SCHEMBL625898 | 0.91 | PPARA (0.48) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL625897 | 0.91 | PPARA (0.48) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL626559 | 0.81 | CTSK (0.40) | CTSKACE | |
| SCHEMBL625890 | 0.81 | PPARA (0.47) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL625889 | 0.81 | PPARA (0.47) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL3935572 | 0.80 | PPARA (0.54) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL3935560 | 0.80 | PPARA (0.54) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL12112869 | 0.78 | KLK5 (0.50) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL1305832 | 0.78 | KLK5 (0.50) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434696-B2 | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives | SANOFI (FR) | 2016-09-06 | — | — | US | disclosed |
| US-8877926-B2 | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives | SANOFI (FR) | 2014-11-04 | — | — | US | disclosed |
| EP-2603491-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI SA (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-20130211085-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI (FR) | 2013-08-15 | — | — | US | disclosed |
| EP-2603491-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI (FR) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012019967-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI (FR) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211085-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | C9, DDT, IDUA | REN 50/4885CTSK 3414/4885CTSS 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.